Akif Ayaz

Akif Ayaz

Auto-generated profile, based on publicly available information

Akif Ayaz

Genetic Diseases Diagnosis and Evaluation Center, İstinye University, İstanbul, Türkiye

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2020 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Closed access
RÖRecep Öztürk
Recep Öztürk
YTYeşim TAŞOVA
Yeşim TAŞOVA
AAAkif Ayaz
Akif Ayaz
COVID-19 caused by a novel agent SARS-CoV-2 progressed to a pandemic condition and resulted in a major public health concern worldwide, leading to social and economic issues at the same time. The pathogenesis of COVID-19 starts with the bonding of the virus to ACE-2 receptors expressed in many tissues, and the triggered excessive immune response plays a critical role in the course of the disease. The cytokine storm that occurs upon excessive production of pro-inflammatory cytokines is considered responsible for the severe progression of the disease and the organ damage. However, the accurate pathophysiological mechanism of the disease, which progresses with various clinical presentations, is still substantially unknown. While various studies have been conducted on the effect of genetic polymorphism on the course and severity of the disease, the presence of a significant effect has not been proven yet. The clinical course of the disease is variable, with clinical representation ranging from 81% mild course to 14% severe course along with 5% critical course in patients. Asymptomatic course is considered to be higher than expected, although its frequency is not known exactly. Older adults and those with comorbidities are exposed to a more severe disease course. The disease progress with various symptoms, such as fever, cough, dyspnea, malaise, myalgia, taste and smell dysfunctions, diarrhea, and headache. A range of complications (Acute Respiratory Distress Syndrome, thromboembolic conditions, arrhythmia and cardiac events, secondary infections) could be seen during the course of the disease. Varied laboratory tests are vital to determine the severity and prognosis of the disease, along with the condition and exposure of the affected systems during the course of COVID-19.

13 December 2022 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
TUTuğçe Aksu Uzunhan
Tuğçe Aksu Uzunhan
BEBiray Ertürk
Biray Ertürk
KAKürşad Aydın
Kürşad Aydın
AAAkif Ayaz
Akif Ayaz
UAUmut Altunoğlu
Umut Altunoğlu
HKHülya Kayserili
Hülya Kayserili

15 December 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
AAAkif Ayaz
Akif Ayaz
ADAsli Guner Ozturk Demir
Asli Guner Ozturk Demir
GOGurkan Ozturk
Gurkan Ozturk
MKMehmet Kocak
Mehmet Kocak
Reverse transcription polymerase chain reaction (RT-PCR) testing is indispensable in management of the coronavirus disease 2019 (COVID-19) pandemic. However, with the emergence of new variants of severe acute respiratory syndrome coronavirus-2, the cause of COVID-19, the screening capacity of RT-PCR testing is overburdened, and new strategies and capabilities need to be established. One option is pooled RT-PCR testing. This study used various mixtures of COVID-19 samples known to be negative and positive, and investigated the impact of pool size and mixture level on final cycle threshold (Ct) values. More specifically, 5, 10 and 20 negative samples were combined with one, two or three low Ct or high Ct positive samples. Average baseline Ct and numbers of high and low Ct samples in the pool were found to be the main drivers of the final Ct value, making detectability easier. Pool size was not significantly associated with final Ct, but was suggestive. A pooled RT-PCR testing strategy does not reduce the sensitivity of RT-PCR, and thus provides a practical way to expand RT-PCR screening capacity in pandemic management. The pool size was not found to be significant, so it is recommended that a pool size of 20 would be a practical number to reduce the time taken to obtain the results and the cost of RT-PCR testing.

18 March 2022 in Medeniyet Medical Journal
Verified
Journal Article
Open access
EGElif Yilmaz Gulec
Elif Yilmaz Gulec
AGAlper Gezdirici
Alper Gezdirici
AAAkif Ayaz
Akif Ayaz
FOFatma Nihal Ozturk
Fatma Nihal Ozturk
IPIbrahim Polat
Ibrahim Polat
Low estriol (uE3) levels in the second-trimester screening for Down syndrome may be the result of fetal demise, congenital abnormalities, or some genetic hormonal disorders of the fetus. Although X-linked ichthyosis, a microdeletion syndrome with mild ichthyosis, which causes steroid sulfatase (STS) deficiency, is the most common genetic cause, second-trimester screening tests calculate the risk for a less common and severe disorder known as the Smith Lemli Opitz syndrome (SLOS). We aimed to investigate the outcomes of pregnancies with low uE3 levels in Down syndrome screening and emphasize the high prevalence of STS deficiency instead of SLOS in such cases. Fifteen pregnancies with very low uE3 levels and high risk for trisomy and/or SLOS in screening tests were evaluated and tested for STS deficiency and SLOS. Seven of the pregnancies had STS microdeletion syndrome, while additional two cases were supposed to have STS gene mutation according to family and/or postnatal history. Although one fetal death was recorded, no chromosomal abnormality, SLOS, or congenital malformation was recorded in our series. SLOS is a very severe and rare syndrome. The risk estimation for SLOS in screening tests causes stress for pregnant women and healthcare givers. We recommend the addition of risk estimation for STS deficiency when a low uE3 level is detected in the screening test.

23 June 2022 in Medeniyet Medical Journal
Verified
Journal Article
Open access
AAAkif Ayaz
Akif Ayaz
AGAlper Gezdirici
Alper Gezdirici
EGElif Yilmaz Gulec
Elif Yilmaz Gulec
OOOzge Ozalp
Ozge Ozalp
AKAbdullah Huseyin Koseoglu
Abdullah Huseyin Koseoglu
SYSinem Yalcintepe
Sinem Yalcintepe
This study aimed to demonstrate the diagnostic value of microarray testing in autism spectrum disorder, intellectual disability, and multiple congenital anomalies of unknown etiology, as well as to report some potential candidate genes for autism. Microarray analysis records between January 2016 and December 2017 from two Genetic Diagnostic Centers in Turkey, Kanuni Sultan Suleyman and Adana Numune Training and Research Hospital, were compiled. Detected copy number variations (CNVs) were classified as benign, likely benign, variants of uncertain significance (VUS), likely pathogenic, and pathogenic according to American College of Medical Genetics and Genomics guidelines. The clinical findings of the some patients and the literature data were compared. In 109 (24.5%) of 445 patients, a total of 163 CNVs with reporting criterion feature were detected. Sixty-nine (42%) and 8 (5%) of these were evaluated as pathogenic and likely pathogenic, respectively. Fifteen (9%) CNVs were also evaluated as VUS. Pathogenic or likely pathogenic CNVs were detected in 61 (13.6%) of 445 patients. We found that the probability of elucidating the etiology of microarray method in autism spectrum disorder, intellectual disability, and multiple congenital anomalies is 13.6% with a percentage similar to the literature. We suggest that the MYT1L, PXDN, TPO, and AUTS2 genes are all strong candidate genes for autism spectrum disorders. We detailed the clinical findings of the cases and reported that some CNV regions in the genome may be associated with autism.

23 August 2022 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
AAAkif Ayaz
Akif Ayaz
ZDZeynep Doğru
Zeynep Doğru
BKBetül Kılıç
Betül Kılıç
BSBarış Ethem Süzek
Barış Ethem Süzek